Oral Antimetabolite After Surgery Associated With Survival Benefit in Biliary Tract Cancer
January 26th 2022Patients with biliary tract cancer achieved a better survival outcome after receiving treatment with an oral antimetabolite following surgical resection than patients who only were treated with surgery.
Read More
Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’
January 6th 2022An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.
Read More
Pre-Surgical Keytruda Provides Promising Advancement in TNBC Treatment
December 20th 2021Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.
Read More
Imbruvica And Rituxan Bests Standard-of-Care Regimen in Patients With Previously Untreated CLL
December 14th 2021The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.
Read More